# Huacapu (Minquartia guianensis)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/huacapu
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-30
**Evidence Score:** 2 / 10
**Category:** Amazonian
**Also Known As:** Minquartia guianensis, Huacapu bark, Amazon ironwood, Bulletwood, Ironwood bark, Peruvian huacapu

## Overview

Huacapu (Minquartia guianensis) is an Amazonian hardwood tree whose primary bioactive compound, minquartynoic acid, demonstrates cytotoxic and antiprotozoal activity in laboratory settings. This acetylenic fatty acid disrupts cellular processes in cancer cell lines and interferes with the survival mechanisms of malaria and leishmania parasites in vitro.

## Health Benefits

• May exhibit antitumor properties, as in vitro studies show minquartynoic acid is cytotoxic to cancer cell lines, but further research is needed. • Demonstrates potential antiprotozoal activity against malaria and leishmania parasites, based on preliminary in vitro studies. • Possesses [antiviral](/ingredients/condition/immune-support) effects, with activity against HIV noted at 2.2 mcg/ml in vitro. • Shows antibacterial activity, affecting 63% of Gram-positive and 70% of Gram-negative bacteria in studies. • Traditionally used for treating viral infections and as an antiseptic wound healer, though clinical evidence is limited.

## Mechanism of Action

Minquartynoic acid, a C18 acetylenic fatty acid isolated from Minquartia guianensis bark and wood, induces cytotoxicity in cancer cell lines through disruption of mitochondrial membrane integrity and induction of apoptotic pathways. Against protozoan parasites such as Plasmodium falciparum and Leishmania spp., it is thought to inhibit key metabolic enzymes involved in parasite [energy metabolism](/ingredients/condition/energy), though the exact molecular targets have not been fully characterized. The [antiviral](/ingredients/condition/immune-support) effects are hypothesized to involve interference with viral replication machinery, potentially through inhibition of reverse transcriptase or viral protease activity, based on structural analogy with other polyacetylenic compounds.

## Clinical Summary

Research on huacapu remains limited almost entirely to in vitro and preliminary phytochemical studies, with no published randomized controlled trials in humans as of current literature. In vitro cytotoxicity assays have demonstrated that minquartynoic acid exhibits activity against several cancer cell lines, including leukemia and solid tumor lines, at micromolar concentrations, though these findings have not been replicated in animal models or human trials. Antiprotozoal activity against Plasmodium falciparum and Leishmania donovani has been observed in cell-based assays, providing preliminary rationale for traditional Amazonian use in treating fever and parasitic infections. The overall evidence base is very early-stage, and no clinical efficacy or safety data exist to support therapeutic use in humans.

## Nutritional Profile

Huacapu (Minquartia guianensis) bark and wood are primarily utilized for medicinal and structural purposes rather than as a food source, so comprehensive macronutrient data is limited. Bioactive compounds are the most documented constituents: Minquartynoic acid (a C18 polyacetylenic fatty acid) is the principal bioactive compound, identified in bark extracts and responsible for much of the reported biological activity; concentrations vary by extraction method but are present in meaningful quantities in ethanolic and methanolic bark extracts. Phenolic compounds including flavonoids and tannins are present in the bark, contributing to [antioxidant](/ingredients/condition/antioxidant) capacity. Alkaloids have been detected in preliminary phytochemical screenings of bark tissue. Terpenoids and sterols have also been reported in bark extracts. The heartwood is exceptionally dense (density ~1.0–1.1 g/cm³) and rich in structural polyphenols that confer decay resistance. As a non-staple Amazonian tree bark medicine, macronutrient content (protein, carbohydrate, fat) is not meaningfully characterized in available literature. Bioavailability of minquartynoic acid and associated polyacetylenes is poorly studied in vivo; most activity data derives from in vitro assays. No significant vitamin or mineral content has been documented for the bark preparations commonly used.

## Dosage & Preparation

Traditional suggestions include a bark powder decoction (1 tsp per cup of water, boiled for 20 minutes, 1/2 cup twice daily) or a 1:4 ethanol extract (2 ml, 2-3 times daily orally or topically). Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

No formal human safety studies, toxicology profiles, or established safe dosage ranges exist for huacapu or isolated minquartynoic acid in supplement form. Given that minquartynoic acid demonstrates cytotoxic activity in vitro, there is a theoretical risk of toxicity at higher concentrations, and use without medical supervision is inadvisable. Potential interactions with anticoagulant drugs, antiparasitic medications, or chemotherapeutic agents cannot be ruled out due to overlapping mechanisms and a complete absence of pharmacokinetic data. Huacapu is contraindicated during pregnancy and breastfeeding due to lack of safety data and the cytotoxic nature of its primary compound.

## Scientific Research

No human clinical trials or meta-analyses reported in available sources; research is limited to in vitro and animal studies. Preclinical studies include cytotoxicity assays and antiprotozoal screenings, but no PubMed PMIDs are available for human trials.

## Historical & Cultural Context

In Amazonian traditional medicine, particularly within Peruvian indigenous systems, huacapu bark has been used for centuries to treat viral infections, cancer, intestinal parasites, and as an antiseptic. It has also been employed for malaria and rheumatism.

## Synergistic Combinations

Cat's claw, Pau d'arco, Maca, Camu camu, Chanca piedra

## Frequently Asked Questions

### What is minquartynoic acid and why is it important in huacapu?

Minquartynoic acid is a C18 acetylenic fatty acid and the principal bioactive compound isolated from the bark and wood of Minquartia guianensis. It is responsible for the plant's observed cytotoxic, antiprotozoal, and antiviral activities in laboratory studies, making it the compound of greatest pharmacological interest in huacapu research.

### Can huacapu kill cancer cells?

In vitro studies have shown that minquartynoic acid from huacapu is cytotoxic to certain cancer cell lines, including leukemia and solid tumor lines, at micromolar concentrations. However, no animal studies or human clinical trials have been conducted, so it is not accurate to claim huacapu treats or prevents cancer in people.

### Is huacapu effective against malaria?

Preliminary in vitro studies demonstrate that minquartynoic acid exhibits antiprotozoal activity against Plasmodium falciparum, the parasite responsible for the most severe form of malaria. While this supports traditional Amazonian use for fever, no clinical trials have validated its efficacy or safety as an antimalarial treatment in humans.

### What are the known side effects of huacapu supplements?

No controlled human studies have documented the side effects of huacapu supplementation, so a complete safety profile does not exist. Because its key compound, minquartynoic acid, is cytotoxic in laboratory settings, there is a theoretical risk of cellular harm at high doses, and consumption without professional medical guidance is not recommended.

### How is huacapu traditionally used in Amazonian medicine?

Indigenous communities in the Amazon basin have traditionally used bark preparations and decoctions from Minquartia guianensis to treat fever, parasitic infections, and as a general tonic, reflecting its observed antiprotozoal and antimicrobial properties. The wood is also prized for its extreme hardness and durability, making it one of the most culturally and economically significant trees in the region.

### What is the current state of clinical research on huacapu's effectiveness in humans?

Most research on huacapu has been conducted in vitro or in animal models, with limited human clinical trials to date. While traditional Amazonian use and preliminary laboratory studies suggest potential benefits against parasites, viruses, and bacteria, robust clinical evidence in human populations remains sparse. Further well-designed clinical studies are needed before huacapu can be recommended as a primary treatment for any condition.

### Is huacapu safe to use during pregnancy or while breastfeeding?

There is insufficient safety data on huacapu use during pregnancy and breastfeeding, and it should be avoided during these periods without medical supervision. Traditional use in Amazonian communities does not guarantee safety for pregnant or lactating women, as systemic exposure and fetal effects have not been adequately studied. Consult a healthcare provider before using huacapu if you are pregnant, planning to become pregnant, or breastfeeding.

### Does huacapu interact with antiretroviral medications or other prescription drugs?

Specific drug interaction studies with huacapu have not been conducted, though its in vitro antiviral activity suggests potential interactions with HIV medications and other treatments. Because huacapu contains bioactive compounds like minquartynoic acid that may affect metabolic pathways, it could theoretically interfere with prescription medications. Anyone taking prescription drugs, particularly antiretrovirals, immunosuppressants, or antiparasitic agents, should consult their healthcare provider before using huacapu supplements.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*